Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Danish (OMX) Healthcare Sector Analysis

UpdatedFeb 28, 2026
DataAggregated Company Financials
Companies21
  • 7D-15.7%
  • 3M-21.9%
  • 1Y-55.8%
  • YTD-23.3%

Over the last 7 days, the Healthcare industry has dropped 16%, driven by a pullback from Novo Nordisk of 21%. Meanwhile, Demant actually outperformed within the industry, gaining 8.1% in the last week. The industry has fallen 56% in the last year. As for the next few years, earnings are expected to grow by 4.4% per annum.

Sector Valuation and Performance

Has the Danish Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sun, 01 Mar 2026DKK 1.5tDKK 447.7bDKK 131.0b18.7x11.4x3.3x
Tue, 27 Jan 2026DKK 2.3tDKK 453.4bDKK 136.7b18.6x16.5x5x
Thu, 25 Dec 2025DKK 2.0tDKK 453.7bDKK 136.8b17.1x14.4x4.3x
Sat, 22 Nov 2025DKK 1.9tDKK 454.4bDKK 137.1b17.1x13.5x4.1x
Mon, 20 Oct 2025DKK 2.0tDKK 447.5bDKK 141.7b19x14.4x4.5x
Wed, 17 Sep 2025DKK 2.1tDKK 447.0bDKK 141.6b19.1x14.7x4.7x
Fri, 15 Aug 2025DKK 1.9tDKK 444.6bDKK 140.3b27.8x13.5x4.3x
Sun, 13 Jul 2025DKK 2.4tDKK 423.1bDKK 124.5b29.9x19.3x5.7x
Tue, 10 Jun 2025DKK 2.7tDKK 423.8bDKK 124.7b30.7x21.3x6.3x
Thu, 08 May 2025DKK 2.4tDKK 422.7bDKK 124.7b22x19.5x5.7x
Sat, 05 Apr 2025DKK 2.4tDKK 409.5bDKK 121.3b22.8x19.4x5.8x
Mon, 03 Mar 2025DKK 3.4tDKK 410.1bDKK 121.4b28.6x27.9x8.3x
Wed, 29 Jan 2025DKK 3.3tDKK 387.4bDKK 111.3b29x29.9x8.6x
Fri, 27 Dec 2024DKK 3.3tDKK 387.4bDKK 111.3b29.8x29.5x8.5x
Sun, 24 Nov 2024DKK 3.9tDKK 387.4bDKK 111.3b31x35x10.1x
Tue, 22 Oct 2024DKK 4.2tDKK 372.1bDKK 107.2b37.6x38.9x11.2x
Thu, 19 Sep 2024DKK 4.5tDKK 371.9bDKK 107.1b36.1x42.2x12.2x
Sat, 17 Aug 2024DKK 4.7tDKK 370.7bDKK 107.0b37.2x43.9x12.7x
Mon, 15 Jul 2024DKK 4.9tDKK 355.2bDKK 106.2b35.5x46.6x13.9x
Wed, 12 Jun 2024DKK 4.9tDKK 355.3bDKK 106.2b35.7x46.3x13.9x
Fri, 10 May 2024DKK 4.5tDKK 355.3bDKK 106.5b34.6x42.3x12.7x
Sun, 07 Apr 2024DKK 4.5tDKK 341.2bDKK 99.6b37.4x44.7x13x
Tue, 05 Mar 2024DKK 4.5tDKK 340.0bDKK 98.9b38x45.6x13.3x
Thu, 01 Feb 2024DKK 4.0tDKK 320.8bDKK 90.1b31.8x44.2x12.4x
Sat, 30 Dec 2023DKK 3.6tDKK 320.4bDKK 90.0b32.8x40.4x11.3x
Mon, 27 Nov 2023DKK 3.7tDKK 320.5bDKK 90.0b32.8x41.2x11.6x
Wed, 25 Oct 2023DKK 3.5tDKK 305.5bDKK 82.2b27.6x42.9x11.5x
Fri, 22 Sep 2023DKK 3.4tDKK 305.5bDKK 82.2b34.4x41.4x11.1x
Sun, 20 Aug 2023DKK 3.3tDKK 303.2bDKK 81.2b36.8x40.8x10.9x
Tue, 18 Jul 2023DKK 2.9tDKK 286.9bDKK 75.4b39.3x38.9x10.2x
Thu, 15 Jun 2023DKK 3.0tDKK 287.1bDKK 75.5b40x39.9x10.5x
Sat, 13 May 2023DKK 3.2tDKK 284.8bDKK 75.0b41.2x43x11.3x
Mon, 10 Apr 2023DKK 3.0tDKK 272.4bDKK 68.5b39.4x43.5x10.9x
Wed, 08 Mar 2023DKK 2.8tDKK 292.6bDKK 69.2b39.2x40.9x9.7x
Price to Earnings Ratio

40.9x


Total Market Cap: DKK 2.8tTotal Earnings: DKK 69.2bTotal Revenue: DKK 292.6bTotal Market Cap vs Earnings and Revenue0%0%0%
Danish Healthcare Sector Price to Earnings3Y Average 32.7x202420252026
Current Industry PE
  • Investors are pessimistic on the Danish Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 11.4x which is lower than its 3-year average PE of 32.7x.
  • The 3-year average PS ratio of 9.3x is higher than the industry's current PS ratio of 3.3x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 24% per year over the last three years.
  • Revenues for these companies have grown 15% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Danish Healthcare sector?

DK Market-7.96%
Healthcare-15.66%
Life Sciences4.71%
Medical Equipment2.04%
Biotech-1.50%
Healthtech-4.72%
Healthcare Services-10.14%
Pharma-19.68%
Industry PE
  • Investors are most optimistic about the Healthcare Services industry which is trading above its 3-year average PE ratio of 402x.
    • Analysts are expecting annual earnings growth of 85.3%, which is higher than its past year's earnings decline of 99.7% per year.
Forecasted Growth
  • Analysts are most optimistic on the Healthcare Services industry, expecting annual earnings growth of 85% over the next 5 years.
  • This is better than its past earnings decline of 100% per year.
  • In contrast, the Life Sciences industry is expected to see its earnings decline by 23% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
DEMANT DemantDKK 196.808.1%
+DKK 3.1b		-24.0%PE17.5x
ALK B ALK-AbellóDKK 220.402.7%
+DKK 1.3b		44.0%PE40.8x
COLO B ColoplastDKK 488.001.0%
+DKK 1.1b		-36.1%PE27.5x
CHEMM ChemoMetecDKK 420.405.1%
+DKK 355.0m		-27.6%PE41.3x
GUBRA GubraDKK 391.004.3%
+DKK 261.5m		-30.7%PE3.7x

Latest News

GUBRA
DKK 391.00
Gubra
7D
4.3%
1Y
-30.7%
NOVO B
DKK 237.90
Novo Nordisk
7D
-21.0%
1Y
-63.1%
COLO B
DKK 488.00
Coloplast
7D
1.0%
1Y
-36.1%

COLO B: Reset P/E And Dividend Will Support Future Re Rating

Analysts have trimmed their DKK price targets on Coloplast, reflected in a lower fair value estimate from DKK 615 to DKK 588, as they factor in slightly more cautious assumptions on growth, margins and future P/E multiples following recent target reductions from several research houses. Analyst Commentary Bullish Takeaways Bullish analysts still see room for upside from current levels, even with reduced DKK price targets.
ALK B
DKK 220.40
ALK-Abelló
7D
2.7%
1Y
44.0%

ALK B: Future Returns Will Rely On Expanded Anaphylaxis Indications And Stronger Margins

Analysts have nudged their price target on ALK-Abelló up from DKK 249 to DKK 255, reflecting updated assumptions that combine slightly lower expected revenue growth with a higher projected profit margin and a modestly lower future P/E multiple. What's in the News ALK Abelló issued earnings guidance for 2026, indicating an expectation of continued double digit revenue growth and higher earnings, with revenue projected to grow 11 to 15% in local currencies (company guidance).
ZEAL
DKK 363.80
Zealand Pharma
7D
-7.4%
1Y
-45.1%

ZEAL: Positive Immunology Data And Metabolic Partnership Will Support Future Upside

Analysts have trimmed their price target on Zealand Pharma by DKK 5 to reflect updated assumptions for revenue growth, profit margins and a higher forward P/E. They have kept the overall discount rate broadly in line with prior views.
GMAB
DKK 1,848.50
Genmab
7D
-0.3%
1Y
14.9%
AMBU B
DKK 79.50
Ambu
7D
-2.4%
1Y
-39.5%

AMBU B: Share Buybacks And Margin Discipline Will Support Future Upside

The analyst price target for Ambu has been trimmed by DKK 1 to DKK 138, as analysts factor in slightly more cautious assumptions on growth, margins and discount rates following recent price target adjustments, such as the DKK 12 cut highlighted by JPMorgan. Analyst Commentary Bullish analysts remain focused on how Ambu can justify its current valuation through consistent execution on its growth plans, even as some price targets, including the DKK 12 adjustment flagged by JPMorgan, are recalibrated.
DEMANT
DKK 196.80
Demant
7D
8.1%
1Y
-24.0%

DEMANT: Recent Rating Upgrade May Support Future Upside Despite Softer Margins

The updated analyst price target for Demant has moved slightly lower to about DKK 232 from roughly DKK 238, as analysts balance a modestly higher assumed revenue growth rate against slightly softer margin expectations and a higher discount rate, with recent Street research showing a mix of target cuts from several banks and one upgrade to Buy at DKK 230. Analyst Commentary Recent Street research around Demant reflects a split view, with one Upgrade to Buy around DKK 230 contrasting with several lower price targets and at least one downgrade.
HLUN B
DKK 38.74
H. Lundbeck
7D
-3.2%
1Y
-3.2%

HLUN B: Positive Neuroscience Pipeline Data Will Support Constructive Medium Term Outlook

Analysts have trimmed their DKK price target on H. Lundbeck from about DKK 47.05 to DKK 44.95, citing updated assumptions for revenue growth, profit margins, as well as a slightly higher future P/E multiple and discount rate.
NNIT
DKK 40.25
NNIT
7D
-4.6%
1Y
-50.1%
BAVA
DKK 197.50
Bavarian Nordic
7D
0.2%
1Y
17.5%

BAVA: Share Buybacks And Latin America Vaccine Deal Will Support Upside

Analysts now keep their DKK 250 price target for Bavarian Nordic intact, as slightly higher discount and future P/E assumptions together with a modestly stronger profit margin view offset softer revenue growth expectations. What's in the News Bavarian Nordic issued earnings guidance for fiscal 2026, indicating expected revenue in the range of DKK 5,000 million to DKK 5,200 million (Corporate guidance).
CHEMM
DKK 420.40
ChemoMetec
7D
5.1%
1Y
-27.6%
BIOPOR
DKK 0.91
BioPorto
7D
-5.5%
1Y
-39.7%
PEG
DKK 0.10
Pharma Equity Group
7D
7.1%
1Y
-27.8%
SMSMED
DKK 3.28
Scandinavian Medical Solutions
7D
-10.1%
1Y
-44.6%

Sentiment Still Eluding Scandinavian Medical Solutions A/S (CPH:SMSMED)

Jan 27
Sentiment Still Eluding Scandinavian Medical Solutions A/S (CPH:SMSMED)
STRAP
DKK 624.00
Strategic Partners
7D
4.0%
1Y
-24.4%